Nanotechnology-driven drug delivery systems for breast cancer: A review
Source abstract
Abstract
Breast cancer (BC) remains a global health challenge, with treatment limitations from systemic toxicity, poor drug bioavailability, and multidrug resistance (MDR). Recent advancements in nanotechnology have revolutionized drug delivery systems (DDS), offering targeted, controlled, and synergistic therapeutic strategies. This review explores cutting-edge micro- and nanocarriers, including liposomes (Lips), nanoparticles (NPs), metal-organic frameworks (MOFs), exosomes and nanofibers (NFs)-designed to optimize the delivery of chemotherapeutic agents. Key design parameters are critically analyzed for their roles in optimizing drug encapsulation, tumor specificity, and biocompatibility. We highlight innovations in carrier engineering that enable biological modulation. Furthermore, co-delivery systems combining chemotherapy drugs with siRNA, P-glycoprotein inhibitors, or photothermal agents demonstrate remarkable success in reversing MDR in vitro and in vivo. Despite progress, challenges such as tumor heterogeneity, long-term carrier safety, and cost-effectiveness require further investigation. This review underscores the transformative potential of nanotechnology-driven DDS in precision oncology, paving the way for next-generation therapies to combat breast BC.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Epidemiological characteristics of and risk factors for breast cancer in the world
2. Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992-201610.1186/s13058-021-01400-3 ↗
3. Recent advances in diagnostic and therapeutic approaches for breast cancer: a comprehensive review10.2174/1381612827666210303141416 ↗
4. Cost-effectiveness of pharmacologic treatment options for women with endocrine-refractory or triple-negative metastatic breast cancer10.1200/JCO.21.02473 ↗
5. Targeting DKK1 enhances the antitumor activity of paclitaxel and alleviates chemotherapy-induced peripheral neuropathy in breast cancer10.1186/s12943-024-02067-y ↗
6. Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)/HER2(−) breast cancer: a randomized phase 3 trial10.1038/s41591-024-03415-7 ↗
7. Clinical databases for breast cancer research10.1007/978-981-32-9620-6_26 ↗
8. Care for breast cancer survivors10.1007/978-981-32-9620-6_27 ↗
9. Recent advances in chitosan-based materials; the synthesis, modifications and biomedical applications10.1016/j.carbpol.2023.121318 ↗
10. Metastatic and triple-negative breast cancer: challenges and treatment options10.1007/s13346-018-0551-3 ↗
11. Non-steroidal anti-inflammatory drugs increase cisplatin, paclitaxel, and doxorubicin efficacy against human cervix cancer cells10.3390/ph13120463 ↗
12. Nanoscale metal-organic frameworks for cancer immunotherapy10.1021/acs.accounts.0c00313 ↗
13. Polymeric nanoparticles for drug delivery10.1021/acs.chemrev.3c00705 ↗
14. Isolation and characterization of exosomes for cancer research10.1186/s13045-020-00987-y ↗
15. Stimuli-responsive polymer-based nanosystems for cancer theranostics10.1021/acsnano.3c06019 ↗
16. Novel dendritic polyglycerol-conjugated, mesoporous silica-based targeting nanocarriers for co-delivery of doxorubicin and tariquidar to overcome multidrug resistance in breast cancer stem cells10.1016/j.jconrel.2020.11.015 ↗
17. Unprecedented inhibition of P-gp activity by a novel ruthenium-cyclopentadienyl compound bearing a bipyridine-biotin ligand10.1016/j.ejmech.2018.12.022 ↗
18. Co-delivery of paclitaxel and cisplatin in poly(2-oxazoline) polymeric micelles: implications for drug loading, release, pharmacokinetics and outcome of ovarian and breast cancer treatments10.1016/j.biomaterials.2018.10.032 ↗
19. Paclitaxel: what has been done and the challenges remain ahead10.1016/j.ijpharm.2017.05.016 ↗
20. Novel dendritic polyglycerol-conjugated, mesoporous silica-based targeting nanocarriers for co-delivery of doxorubicin and tariquidar to overcome multidrug resistance in breast cancer stem cells10.1016/j.jconrel.2020.11.015 ↗
21. pH-responsive lipid polymer hybrid nanoparticles (LPHNs) based on poly (β-amino ester) as a promising candidate to resist breast cancers10.1016/j.jddst.2020.102102 ↗
22. Non-steroidal anti-inflammatory drugs increase cisplatin, paclitaxel, and doxorubicin efficacy against human cervix cancer cells10.3390/ph13120463 ↗
23. Tumor-targeting pH/redox dual-responsive nanosystem epigenetically reverses cancer drug resistance by co-delivering doxorubicin and GCN5 siRNA10.1016/j.actbio.2021.09.002 ↗
24. Star polyester-based folate acid-targeting nanoparticles for doxorubicin and curcumin co-delivery to combat multidrug-resistant breast cancer10.1080/10717544.2021.1960926 ↗
25. Metastatic and triple-negative breast cancer: challenges and treatment options10.1007/s13346-018-0551-3 ↗
26. Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
27. Adsorption and sustained release of doxorubicin from N-carboxymethyl chitosan/polyvinyl alcohol/poly(ε-caprolactone) composite and core-shell nanofibers10.1016/j.jddst.2021.102937 ↗
28. Targeted delivery of doxorubicin liposomes for HER-2+ breast cancer treatment10.1208/s12249-020-01743-8 ↗
29. Maleimide-functionalized liposomes: prolonged retention and enhanced efficacy of doxorubicin in breast cancer with low systemic toxicity10.3390/molecules27144632 ↗
30. Reversal of multidrug resistance by apolipoprotein A1-modified doxorubicin liposome for breast cancer treatment10.3390/molecules26051280 ↗
31. An acoustic/thermo-responsive hybrid system for advanced doxorubicin delivery in tumor treatment10.1039/C9BM01794A ↗
32. Folate-coated, long-circulating and pH-sensitive liposomes enhance doxorubicin antitumor effect in a breast cancer animal model
33. Co-delivery of Poria cocos extract and doxorubicin as an 'all-in-one' nanocarrier to combat breast cancer multidrug resistance during chemotherapy
34. Coencapsulation of disulfiram and doxorubicin in liposomes strongly reverses multidrug resistance in breast cancer cells10.1016/j.ijpharm.2020.119191 ↗
35. NIR-activated thermosensitive liposome-gold nanorod hybrids for enhanced drug delivery and stimulus sensitivity10.1021/acsbiomaterials.2c01142 ↗
36. DNAzyme-based nanoflowers for reversing P-glycoprotein-mediated multidrug resistance in breast cancer10.1016/j.jcis.2021.11.031 ↗
37. DOX-loaded peptide dendritic copolymer nanoparticles for combating multidrug resistance by regulating the lysosomal pathway of apoptosis in breast cancer cells10.1039/C9TB02130B ↗
38. Doxorubicin-loading core-shell pectin nanocell: a novel nanovehicle for anticancer agent delivery with multidrug resistance reversal10.1371/journal.pone.0235090 ↗
39. Pluronic micelles with suppressing doxorubicin efflux and detoxification for efficiently reversing breast cancer resistance10.1016/j.ejps.2020.105275 ↗
40. Synergistic combination of bioactive hydroxyapatite nanoparticles and the chemotherapeutic doxorubicin to overcome tumor multidrug resistance10.1002/smll.202007672 ↗
41. A 3D in vitro triculture hybrid model recapitulating tumor stromal interaction of triple-negative breast cancer as a high throughput anticancer drug screening platform
42. Combination therapy of breast cancer by codelivery of doxorubicin and survivin siRNA using polyethylenimine modified silk fibroin nanoparticles10.1021/acsbiomaterials.0c01511 ↗
43. Stimuli-responsive, dual-function prodrug encapsulated in hyaluronic acid micelles to overcome doxorubicin resistance10.1016/j.actbio.2021.11.050 ↗
44. Development and evaluation of core-shell nanocarrier system for enhancing the cytotoxicity of doxorubicin/metformin combination against breast cancer cell line10.1016/j.xphs.2022.05.018 ↗
45. Formaldehyde-doxorubicin dual polymeric drug delivery system for higher efficacy and limited cardiotoxicity of anthracyclines10.1016/j.eurpolymj.2020.110210 ↗
46. A novel targeted co-delivery system for transfer of epirubicin and antimiR-10b into cancer cells through a linear DNA nanostructure consisting of FOXM1 and AS1411 aptamers10.1016/j.jddst.2021.102521 ↗
47. An application of tumor-associated macrophages as immunotherapy targets: sialic acid-modified EPI-loaded liposomes inhibit breast cancer metastasis10.1208/s12249-022-02432-4 ↗
48. Terminating the renewal of tumor-associated macrophages: a sialic acid-based targeted delivery strategy for cancer immunotherapy10.1016/j.ijpharm.2019.118706 ↗
49. Engineered hyaluronic acid-decorated niosomal nanoparticles for controlled and targeted delivery of epirubicin to treat breast cancer
50. Polyphosphazene-based nanocarriers for the release of camptothecin and epirubicin10.3390/pharmaceutics14010169 ↗
51. Development of epirubicin-loaded biocompatible polymer PLA-PEG-PLA nanoparticles: synthesis, characterization, stability, and in vitro anticancerous assessment10.3390/polym13081212 ↗
52. Controllable drug delivery by Na+/K+ ATPase α1 targeting peptide conjugated DSPE-PEG nanocarriers for breast cancer10.1177/15330338211027898 ↗
53. Enhancement of in vitro antitumour activity of epirubicin in HER2+ breast cancer cells using immunoliposome formulation10.1049/nbt2.12012 ↗
54. Self-assembled dual-targeted epirubicin-hybrid polydopamine nanoparticles for combined chemo-photothermal therapy of triple-negative breast cancer10.2147/IJN.S260477 ↗
55. Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer10.1016/j.ijpharm.2019.118806 ↗
56. Dinarvand, pH-responsive, adorned nanoniosomes for codelivery of cisplatin and epirubicin: synergistic treatment of breast cancer10.1021/acsabm.1c01107 ↗
57. Quatramer™ mediated co-delivery of PI3-Kδ/HDAC6 dual inhibitor augments the anti-cancer efficacy of epirubicin in breast cancer10.1016/j.ejpb.2022.09.003 ↗
58. Selective inhibition of aminopeptidase N by paclitaxel: insights into enzymatic interactions with cytostatics and analgesics in cancers
59. Co-delivery of letrozole and cyclophosphamide via folic acid-decorated nanoniosomes for breast cancer therapy: synergic effect, augmentation of cytotoxicity, and apoptosis gene expression10.3390/ph15010006 ↗
60. Host-guest complexation of cyclophosphamide by carboxylatopillar[6]arene for increasing stability and enhancing its curative effect on breast carcinoma10.1016/j.bmcl.2022.129060 ↗
61. Dual-targeted enzyme-sensitive hyaluronic acid nanogels loading paclitaxel for the therapy of breast cancer10.1016/j.carbpol.2022.119785 ↗
62. Development of a pH-sensitive functionalized metal organic framework: in vitro study for simultaneous delivery of doxorubicin and cyclophosphamide in breast cancer10.1039/D1RA04591A ↗
63. Novel doxorubicin/folate-targeted trans-ferulic acid-loaded PLGA nanoparticles combination: in-vivo superiority over standard chemotherapeutic regimen for breast cancer treatment10.1016/j.biopha.2021.112376 ↗
64. Biotin and arginine modified hydroxypropyl-β-cyclodextrin nanoparticles as novel drug delivery systems for paclitaxel10.1016/j.carbpol.2019.04.024 ↗
65. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy10.1016/j.ejpb.2017.02.020 ↗
66. Paclitaxel: what has been done and the challenges remain ahead10.1016/j.ijpharm.2017.05.016 ↗
67. Nanoparticles for co-delivery of paclitaxel and curcumin to overcome chemoresistance against breast cancer10.1016/j.jddst.2022.104050 ↗
68. Drug-binding albumins forming stabilized nanoparticles for co-delivery of paclitaxel and resveratrol: in vitro/in vivo evaluation and binding properties investigation10.1016/j.ijbiomac.2020.03.060 ↗
69. Folic acid-modified nanoerythrocyte for codelivery of paclitaxel and tariquidar to overcome breast cancer multidrug resistance10.1021/acs.molpharmaceut.9b01148 ↗
70. Laser-responsive multi-functional nanoparticles for efficient combinational chemo-photodynamic therapy against breast cancer10.1016/j.colsurfb.2022.112574 ↗
71. Honokiol nanosuspensions loaded thermosensitive hydrogels as the local delivery system in combination with systemic paclitaxel for synergistic therapy of breast cancer10.1016/j.ejps.2022.106212 ↗
72. Nucleobase-crosslinked poly(2-oxazoline) nanoparticles as paclitaxel carriers with enhanced stability and ultra-high drug loading capacity for breast cancer, Asian
73. Folic acid and poly(ethylene glycol) decorated paclitaxel nanocrystals exhibit enhanced stability and breast cancer-targeting capability
74. Targeting therapy and tumor microenvironment remodeling of triple-negative breast cancer by ginsenoside Rg3 based liposomes10.1186/s12951-022-01623-2 ↗
75. Functionalized lipid nanocarriers for simultaneous delivery of docetaxel and tariquidar to chemoresistant cancer cells10.3390/ph16030349 ↗
76. Non-covalent strategies to functionalize polymeric nanoparticles with NGR peptides for targeting breast cancer10.1016/j.ijpharm.2023.123045 ↗
77. Efficient in vitro and in vivo docetaxel delivery mediated by pH-sensitive LPHNPs for effective breast cancer therapy10.1016/j.colsurfb.2021.111760 ↗
78. Enhanced cytotoxic activity of docetaxel-loaded silk fibroin nanoparticles against breast cancer cells10.3390/polym13091416 ↗
79. An in-vitro quantitative investigation on the synergistic effect of capsaicin and 5-fluorouracil encapsulated into lipid nanocapsules to treat breast cancer10.1080/03639045.2023.2203252 ↗
80. 5-FU@DHA-UiO-66-NH2 potentiates chemotherapy sensitivity of breast cancer cells through a microRNA let-7a-dependent mechanism10.21037/atm-21-5978 ↗
81. A new pH-sensitive CS/Zn-MOF@GO ternary hybrid compound as a biofriendly and implantable platform for prolonged 5-fluorouracil delivery to human breast cancer cells10.1016/j.jallcom.2021.160992 ↗
82. Preparation and characterization of silk fibroin nanoparticles as a potential drug delivery system for 5-fluorouracil10.15171/apb.2019.069 ↗
83. Development of metal-organic frameworks (ZIF-8) as low-cost carriers for sustained release of hydrophobic and hydrophilic drugs: in vitro evaluation of anti-breast cancer and anti-infection effect10.1007/s10876-022-02349-9 ↗
84. Advanced liposome based PEGylated microgel as a novel release system for 5-fluorouracil against MCF-7 cancer cell10.1016/j.eurpolymj.2021.110270 ↗
85. Co-encapsulation of paclitaxel and 5-fluorouracil in folic acid-modified, lipid-encapsulated hollow mesoporous silica nanoparticles for synergistic breast cancer treatment10.1039/D2RA03718A ↗
86. Functionalized PAMAM-based system for targeted delivery of miR-205 and 5-fluorouracil in breast cancer10.1016/j.jddst.2021.102959 ↗
87. Effectiveness of 5-fluorouracil and gemcitabine hydrochloride loaded iron-based chitosan-coated MIL-100 composite as an advanced, biocompatible, pH-sensitive and smart drug delivery system on breast cancer therapy10.1016/j.ijbiomac.2021.12.130 ↗
88. Synthesis of magnetic gold coated poly(ε-caprolactonediol) based polyurethane/poly(N-isopropylacrylamide)-grafted-chitosan core-shell nanofibers for controlled release of paclitaxel and 5-FU10.1016/j.ijbiomac.2019.10.120 ↗
89. Self-assembled silk fibroin nanoparticles loaded with binary drugs in the treatment of breast carcinoma10.2147/IJN.S108633 ↗
90. Fucose decorated solid-lipid nanocarriers mediate efficient delivery of methotrexate in breast cancer therapeutics10.1016/j.colsurfb.2016.05.051 ↗
91. Interaction of methotrexate, folates, and pyridine nucleotides with dihydrofolate reductase: calorimetric and spectroscopic binding studies10.1073/pnas.75.7.3201 ↗
92. Hyaluronic acid-conjugated methotrexate and 5-fluorouracil for targeted drug delivery10.1016/j.ijbiomac.2024.132671 ↗
93. Breast cancer index in premenopausal women with early-stage hormone receptor–positive breast cancer
94. Bioreducible cross-linked core polymer micelles enhance in vitro activity of methotrexate in breast cancer cells10.1039/C6BM00888G ↗
95. In vitro investigation on the magnetic thermochemotherapy mediated by magnetic nanoparticles combined with methotrexate for breast cancer treatment10.1166/jnn.2013.6080 ↗
96. Enhanced antitumor efficacy by methotrexate conjugated pluronic mixed micelles against KBv multidrug resistant cancer10.1016/j.ijpharm.2013.05.015 ↗
97. Fabrication of methotrexate-loaded gold nanoconjugates and its enhanced anticancer activity in breast cancer10.1007/s13205-021-02718-7 ↗
98. Ultrasound-guided chemoradiotherapy of breast cancer using smart methotrexate-loaded perfluorohexane nanodroplets
99. Dual-enhanced pluronic nanoformulated methotrexate-based treatment approach for breast cancer: development and evaluation of in vitro and in vivo efficiency10.3390/pharmaceutics14122668 ↗
100. Co-delivery of STAT3 siRNA and methotrexate in breast cancer cells10.1080/21691401.2022.2030746 ↗